There is evidence that suggests a reciprocal functional link between the serotonergic and the somatostatinergic system in the rat Ž . frontoparietal cortex. However, to date, the role of endogenous 5-hydroxytryptamine serotonin on the regulation of the somatostatin Ž .
Introduction
There is evidence that suggests a reciprocal functional link between the serotonergic and the somatostatinergic system in the rat frontoparietal cortex. This cerebral area is Ž . w x rich in somatostatin SS -containing neurons 36 and SS w x receptors 8 and receives a dense serotonergic innervation w x Ž 22 . In the brain, both SS and 5-hydroxytryptamine sero-. tonin have been implicated in motor and sensory funcw x tions 10, 18, 22, 40 . SS mediates its various functions through receptors that are coupled to GTP-binding proteins Ž .w x G-proteins 34,46 , inducing inhibition of adenylyl cy-Ž . w x w x clase AC 6,7,46 , reduction in calcium currents 54 and w x increases in potassium channel conductance 53 . In the rat cerebral cortex, both 5-hydroxytryptamine 5-HT and 5- prevalence of the latter class. The binding capacity of 5-hydroxytryptamine 5-HT receptors was significantly in-1 creased in the cerebral cortex of rats treated for 10 days with SS, whereas the affinity of 5-hydroxytryptamine 5-w x HT receptors was significantly decreased 37 . Recently, 1 serotonergic axon terminals have been demonstrated to be present on SS-immunoreactive neurons of the rat paravenw x tricular nucleus 26 . Recent studies have also shown that selective serotonergic lesions in rats increase preprosow x matostatin mRNA expression in the striatum 2 . In addition, long-term treatment with 5-hydroxytryptamine uptake inhibitors, such as clomipramine and zimelidine, or with a 5-hydroxytryptamine precursor reduces cerebral SS-like w x immunoreactivity content 24 . On the other hand, SS w x facilitates 5-hydroxytryptamine release 52 and stimulates w x both its synthesis and utilization 13 . Alterations of the somatostatinergic and serotonergic systems have been associated with depression, Alzheimer's disease, schizophre-( )w x nia and Huntington's chorea 23, 42 . To clarify the possible role of endogenous 5-hydroxytryptamine on the regulation of the SS receptor-AC system in the rat brain, we examined the effect of the enhancement of serotonergic neurotransmission by increasing 5-hydroxytryptamine availability in the vicinity of the receptor site with fluoxe-Ž Ž . tine 3-p-trifluoromethylphenoxy -N-methyl-3-phenylpro-. pylamine hydrochloride , a highly selective 5-hydroxytrypw x tamine re-uptake inhibitor 55 . The selectivity and potency of this drug as an inhibitor of the 5-hydroxytryptamine re-uptake pump has aroused considerable interest and is being widely used as a tool for studying the functional role of the serotonergic system and for the treatment of mental w x depression 50 . In addition, we studied the effects of a decrease in serotonergic neurotransmission by reduction of 5-hydroxytryptamine innervation in the neocortex with the w x amphetamine derivate p-chloroamphetamine 12 . Therefore, the present study assessed the acute and chronic effect of fluoxetine and p-chloroamphetamine on the specific binding of SS to its receptors, the ability of SS to Ž . inhibit forskolin FK -stimulated AC activity and the functional activity of guanine nucleotide-binding inhibitory Ž . proteins G -proteins in rat frontoparietal cortical memi branes.
Materials and methods

Materials
Synthetic Tyr 11 -SS was purchased from Universal Bio-Ž . 125 Ž logicals Cambridge, UK ; carrier-free Na I IMS 300, . 100 mCirml was purchased from the Radiochemical Cen-Ž . ter Amersham, UK ; fluoxetine, p-chloroamphetamine, bacitracin, phenylmethylsulphonyl fluoride, guanosine Ž .
X triphosphate GTP , 5 -guanylylimidodiphosphate Ž Ž . . Gpp NH p ; 3-isobutyl-1-methylxanthine and bovine Ž serum albumin were purchased from Sigma St. Louis, . MO, USA . All other reagents were of the highest purity commercially available.
Experimental animals
The animal experiments performed in the present study were conducted under the guidelines of the Animal Care Committee of Alcala University and the experimental protocols have been approved. Wistar rats weighing 200-250 g at the beginning of the treatment were used in all experiments. The rats were housed in groups of five under Ž . controlled room temperature 228C , in a constant 12-h light-dark cycle, with food and water given ad libitum. Fluoxetine and p-chloroamphetamine dissolved in saline were injected i.p. in a volume of 2 mlrkg. In the acute treatment, a single fluoxetine dose of 10 mgrkg i.p. was w x injected as previously described 55 . In the chronic treatment, fluoxetine was injected at a dose of 10 mgrkg i.p. once daily for 14 days. Animals were sacrificed by decapitation 24 h after the last injection as previously described w x 47 . The fluoxetine dose of 10 mgrkg i.p. was observed w x by Wong et al. 55 to alter the response of rat forebrain neurons to 5-hydroxytryptamine. p-Chloroamphetamine w x treatment was carried out as previously described 51 according to the following schemes: a dose of 5 mgrkg of p-chloroamphetamine was administered on days 1, 3 and 5 and the rats were decapitated at 1 or 3 weeks after the first injection. Control animals for each group were injected with saline at identical intervals. The brain was rapidly removed and the frontoparietal cortex was dissected over w x ice according to the method of Glowinski and Iversen 16 .
Measurement of 5-hydroxytryptamine
To assess the destruction of serotonergic neurons in p-chloroamphetamine-treated rats, frontoparietal cortical 5-hydroxytryptamine levels in control and treated rats were measured by high-performance liquid chromatography Ž . w x HPLC with electrochemical detection 48 .
Binding assay
Tyr 11 -SS was radioiodinated by chloramine-T iodinaw x tion according to the method of Greenwood et al. 17 . The Ž . tracer was purified in a Sephadex G-25 fine column which had been equilibrated and eluted with 0.1 M acetic Ž . acid containing bovine serum albumin 0.1% wrv . The specific activity of the purified labelled peptide was f 600 Cirmmol.
Frontoparietal cortical membranes were prepared as w x previously described by Reubi et al. 38 . The frontoparietal cortex was homogenized in 10 mM HEPES-KOH Ž . buffer pH 7.5 with a Brinkmann polytron homogenizer Ž . setting 5, 15 s . The homogenate was spun at 600 = g for 5 min at 48C and the supernatant centrifuged at 48 000 = g for 30 min at 48C. The resulting pellet was suspended in Ž . 10 mM HEPES-KOH pH 7.5 and centrifuged as before. The new pellet was then re-suspended in 50 mM Tris-HCl Ž . buffer pH 7.5 . Samples were stored at y708C until assay. Proteins were assayed by the method of Lowry et al. f 20% of the binding observed in the absence of native peptide and was subtracted from the total bound radioactivity in order to obtain the corresponding specific binding.
The inactivation of I Tyr -SS in the incubation medium after exposure to membranes was studied by observing the w x ability of the peptide to re-bind to fresh membranes 1 .
AC assay
w x AC activity was measured as previously reported 19 with minor modifications. Briefly, rat frontoparietal corti-Ž . cal membranes 0.06 mgrml were incubated with 1.5 mM ATP, 5 mM MgSO , 10 mM GTP and an ATP-regener-4 Ž ating system 7.5 mgrml creatine phosphate and 1 mgrml . creatine kinase , 1 mM 3-isobutyl-1-methylxanthine, 0.1 mM phenylmethylsulphonyl fluoride, 1 mgrml bacitracin, Ž y4 y5 1 mM EDTA and test substances 10 M SS or 10 M . Ž FK in 0.1 ml of 0.025 M triethanolaminerHCl buffer pH . 7.4 . After a 15-min incubation at 308C, the reaction was stopped by heating the mixture for 3 min. After refrigera-Ž tion, 0.2 ml of an alumina slurry 0.75 grml in tri-. ethanolaminerHCl buffer, pH 7.4 was added and the suspension centrifuged. The supernatant was taken to assay -0.05. Each individual experiment was performed in duplicate.
Results
The acute and chronic administration of fluoxetine inw 125 x 11 creased I Tyr -SS binding to rat frontoparietal cortical membranes as compared with controls. This increase was due to a rise in the maximal number of SS receptors as revealed by Scatchard plots of the binding data, without Ž . any change in the binding affinity Table 1 , Fig. 1 .
To assess the functional consequences of the changes in SS binding, experiments were designed to examine the effect of SS on FK-stimulated AC activity in control rats and rats acutely treated with fluoxetine. No significant differences were seen for either the basal or FK-stimulated AC activities between the control and fluoxetine-treated Ž . rats Table 2 . As previously observed, SS inhibited FKstimulated AC activity. When rats were treated with fluoxetine acutely or chronically, the effect of SS on FK-stimulated AC activity was markedly decreased in frontoparietal Ž . cortical membranes Table 2 .
Further experiments explored the effect of fluoxetine on G -proteins in rat frontoparietal cortical membranes by i Ž . determining the ability of low Gpp NH p concentrations to inhibit FK-stimulated AC activity. The inhibitory effect of Ž . Gpp NH p on FK-stimulated AC activity was markedly X Ž Ž . . With the aim of determining the effect of decreased serotonergic neurotransmission on the SS receptor-AC system, a group of rats were treated with p-chloroamphetamine, which depletes 5-hydroxytryptamine levels Ž . in the rat brain Table 3 , leading to a lasting reduction of 5-hydroxytryptamine innervation in the neocortex and other forebrain structures. p-Chloroamphetamine administration leads to a decrease in the number of SS receptors in the frontoparietal cortical membranes, with no change in the Ž . binding affinity Table 1 . No significant differences were seen for either the basal or FK-stimulated AC activities between the control rats and rats treated with p-chloroamphetamine. The capacity of SS to inhibit basal and FK-stimulated AC activity in these experimental groups is shown in Table 4 . The effect of SS on FK-stimulated AC activity was decreased in frontoparietal cortical membranes from p-chloroamphetamine-treated rats as compared to control animals Ž . Table 4 .
Frontoparietal cortical membranes from control and pchloroamphetamine-treated rats showed similar G -protein i Ž . activity data not shown at 1 and 3 weeks after its administration.
Discussion
In the present study, we have shown that the increase of serotonergic transmission induced by acute or chronic administration of fluoxetine, a selective 5-hydroxytryptamine re-uptake inhibitor, leads to a rise in the number of SS receptors, without altering their affinity, in the rat frontoparietal cortex. However, this treatment results in a reduction of the ability of SS to inhibit FK-stimulated AC activity. In addition, the decrease of serotonergic transmission induced by reduction of 5-hydroxytryptamine innervation in the neocortex due to systemic p-chloroamphetaw x mine administration 12 leads to a decrease of the number of SS receptors and of the ability of SS to inhibit FKstimulated AC activity in frontoparietal cortical membranes.
The binding parameters of SS receptors in the control rats were similar to those previously reported by others w x 49 . Recently, five different SS receptor subtypes have w x been cloned 20 and the tissue distribution of the messenger ribonucleic acid for each subtype has been studied in w x w 125 x 11 the rat 4 . The fact that this study with I Tyr -SS shows only one type of SS receptor might be explained by the hypothesis that this radioligand binds to all types of SS receptors with dissociation constants that are virtually identical and cannot be discriminated by Scatchard analysis.
The increase in the number of SS receptors was observed at a concentration of fluoxetine that produces a significant increase in the extraperikaryal 5-hydroxytrypw x tamine concentration in the rat brain 55 , leading to an enhanced activation of synaptic 5-hydroxytryptamine rew x ceptors as observed in functional studies 47 .
5-hydroxytryptamine is known to bind and activate receptors coupled to different signaling pathways. In the rat cerebral cortex, both 5-hydroxytryptamine 5-HT and control on AC, it seems likely that the increase in the number of SS receptors following acute and chronic fluoxetine administration is the result, at least in part, of a decreased activation of a phosphorylation pathway via the Ž . cAMP-dependent protein kinase A PKA . Recently, we found that the administration of a single dose of 5-hydroxytryptamine was accompanied by an increase in the w x number of SS receptors in the rat frontoparietal cortex 33 .
It has been shown that chronic treatment with similar doses of fluoxetine induces an increased serotonergic func- The changes in SS binding were not due to a direct effect of 5-hydroxytryptamine on SS receptors since no change in tracer binding was detected following incubation of fresh frontoparietal cortical membranes with fluoxetine w x or 5-hydroxytryptamine 33 . This is consistent with the absence of any apparent structural analogy between these molecules.
Daily administration of fluoxetine to rats did not change radioligand binding to a -, or a -adrenergic, muscarinic 1 2 w x cholinergic, H -histaminergic or opiate receptors 56 , sug-1 gesting that these neurotransmitter systems are not implicated in the increase of the number of SS receptors found following long-term fluoxetine administration.
Several studies suggest that a central serotonergic mechanism plays a role in the regulation of SS-containing neurons. However, to date, these studies have frequently seemed contradictory. There are studies suggesting that w x 5-hydroxytryptamine may inhibit SS release 9 . This mechanism could be involved in the increase of the number of SS receptors observed following acute and chronic w x fluoxetine administration. In contrast, other authors 2,24 have postulated that augmentation of serotonergic activity probably stimulates SS release in the cerebral cortex and hippocampus. If this is so, the increase of serotonergic neurotransmission induced by fluoxetine administration could lead to a rise of SS levels in the synaptic cleft that, together with the elevation of the number of SS receptors, would increase somatostatinergic neurotransmission. In addition, 5-hydroxytryptamine was found to have no influence on SS release either from cultured cerebral cortical w x w x cells 39 or from hypothalamic tissues 30 .
The effects of p-chloroamphetamine are characterized by an acute release of 5-hydroxytryptamine followed by a marked decrease in forebrain levels of this neurotransmitter; many 5-hydroxytryptamine axon terminals undergo subsequent degeneration, leading to a lasting reduction of 5-hydroxytryptamine innervation in the neocortex and other w x forebrain structures 12 . A possible mechanism for the decrease of the number of SS receptors after p-chloro- ( ) amphetamine administration is that it is secondary to a decreased serotonergic activity; the serotonergic lesion could be removing serotonergic input to somatostatinergic neurons, altering SS release and thereby changing the number of post-synaptic SS receptors. Alternatively, it is possible that some SS receptors are localized pre-synaptically on serotonergic axons and, therefore, the degradation of these axons due to p-chloroamphetamine administration would be responsible for the observed decrease of SS binding.
Basal cAMP levels were unaffected by p-chloroamphetamine and fluoxetine which is in agreement with w x previous studies 51 . Basal and FK-stimulated AC activity was inhibited by SS in all the experimental groups studied w x which is in agreement with the literature 3,35,46 . A very Ž y4 . high concentration of SS 10 M was required to produce this inhibition although the same concentration was w x w x used by Schettini et al. 46 , Bergstrom et al. 3 , Garlind eẗ w x w x al. 14 and Nagao et al. 35 in their studies on SS-mediated AC activity in rat and human brain. However and despite this high concentration, several lines of evidence suggest that the effect of SS is receptor-mediated and is not due to a non-specific inhibitory effect. In this regard, the GTP dependency of the inhibitory effect suggests the involvement of a G-protein in this response. This finding is consistent with binding studies on post-mortem human and rat brain tissues which have shown that the binding of SS to its recognition site is affected by GTP in a manner consistent with the involvement of a G-protein. In addiw x w x tion, Nagao et al. 35 and Shettini et al. 46 have shown that SS-reduced cAMP formation in the rat brain occurs via a G-protein coupled to AC. Overall results, plus the Ž . lack of a SS 1 mM inhibitory effect on basal adenylate cyclase activity in primary cultures of mouse embryonic w x glial cells reported by Chneiweiss et al. 6 would argue against a non-specific inhibitory effect of the neuropeptide.
The ability of SS to inhibit FK-stimulated AC activity is significantly attenuated in frontoparietal cortical membranes from fluoxetine or p-chloroamphetamine-treated rats as compared with their controls. We have assessed possible involvement of AC catalytic subunit and the functional activity of G-protein coupling in this enzymatic response to SS in both treatments. FK-stimulated AC activity was not affected by fluoxetine or p-chloroamphetamine administration which allows us to exclude the possibility that both substances affect the functioning of the AC catalytic subunit. We have also examined the Ž . response of AC to the GTP analogue Gpp NH p as an index of the functional activity of the coupling G-protein.
Ž . The inhibitory effect of Gpp NH p on FK-stimulated AC activity was markedly decreased in frontoparietal cortical membranes from rats acutely and chronically treated with fluoxetine which suggests that there is a less functional G -protein in these membranes that would explain the The present results suggest that under normal circumstances some SS receptors are under a tonic stimulatory control through the serotonergic system. Both the serotonergic and somatostatinergic systems have been implicated in depression as well as in other central nervous system w x disorders 23,42 . These results indicate the existence of serotonergic and somatostatinergic interactions in the rat frontoparietal cortex and suggest that the SS receptor-AC system is implicated in the mechanism of action of the antidepressant drug fluoxetine. Therefore, it is tempting to speculate that the somatostatinergic system may play a role in the pathophysiology of depression.
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